Activation of glucagon-like peptide-1 receptors and skilled reach foraging.
Montoya staircase
electrophysiology
gut-brain axis
motivated behaviours
nucleus accumbens shell
Journal
Addiction biology
ISSN: 1369-1600
Titre abrégé: Addict Biol
Pays: United States
ID NLM: 9604935
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
revised:
15
07
2020
received:
23
03
2020
accepted:
20
07
2020
pubmed:
10
8
2020
medline:
3
11
2021
entrez:
10
8
2020
Statut:
ppublish
Résumé
Glucagon-like peptide-1 receptor (GLP-1R) agonists, such as exendin-4 (Ex4), liraglutide and dulaglutide, regulate glucose homeostasis and are thus used to treat diabetes type II. GLP-1 also contributes towards a variety of additional physiological functions, including suppression of reward and improvement of learning. Acute activation of GLP-1R in the nucleus accumbens (NAc) shell, an area essential for motivation, reduces the motivation to consume sucrose or alcohol when assessed in a simple motor task. However, the effects of repeated administration of the different GLP-1R agonists on behaviours in a more complex motor task are unknown. The aim was therefore to investigate the effects of repeated Ex4, liraglutide or dulaglutide on the motivation and learning of a complex motor tasks such as skilled reach foraging in the Montoya staircase test. To explore the neurophysiological correlates of the different GLP-1R agonists on motivation, ex vivo electrophysiological recordings were conducted. In rats with an acquired skilled reach performance, Ex4 or liraglutide but not dulaglutide reduced the motivation of skilled reach foraging. In trained rats, Ex4 infusion into NAc shell decreased this motivated behaviour, and both Ex4 and liraglutide supressed the evoked field potentials in NAc shell. In rats without prior Montoya experience, dulaglutide but not Ex4 or liraglutide enhanced the learning of skilled reach foraging. Taken together, these findings indicate that the tested GLP-1R agonists have different behavioural outcomes depending on the context.
Identifiants
pubmed: 32770792
doi: 10.1111/adb.12953
pmc: PMC8244104
doi:
Substances chimiques
Glucagon-Like Peptide-1 Receptor
0
Ethanol
3K9958V90M
Liraglutide
839I73S42A
Glucagon-Like Peptide 1
89750-14-1
Exenatide
9P1872D4OL
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e12953Informations de copyright
© 2020 The Authors. Addiction Biology published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction.
Références
Mol Psychiatry. 2018 Jul;23(7):1555-1565
pubmed: 28461695
PLoS One. 2016 May 03;11(5):e0154477
pubmed: 27139195
Obesity (Silver Spring). 2011 Jul;19(7):1342-9
pubmed: 21415845
Neuroreport. 2018 Aug 15;29(12):1046-1053
pubmed: 29927808
J Clin Endocrinol Metab. 2003 Jul;88(7):3082-9
pubmed: 12843147
Psychoneuroendocrinology. 2019 Aug;106:183-194
pubmed: 30999229
Behav Brain Res. 2003 Nov 30;146(1-2):145-57
pubmed: 14643467
Behav Brain Res. 2015 Mar 1;280:84-91
pubmed: 25454351
Neuropsychopharmacology. 2020 Feb;45(3):451-461
pubmed: 31581176
Nat Commun. 2015 Dec 01;6:8918
pubmed: 26621478
Biol Sex Differ. 2016 Jan 16;7:6
pubmed: 26779332
Diabetes Metab Res Rev. 2010 May;26(4):287-96
pubmed: 20503261
Neuropharmacology. 2014 Nov;86:22-30
pubmed: 24998752
J Pharmacol Exp Ther. 2007 Jul;322(1):148-54
pubmed: 17395766
Neuropharmacology. 2012 Apr;62(5-6):1916-27
pubmed: 22227019
Diabetes Obes Metab. 2015 Oct;17(10):974-83
pubmed: 26179187
J Neurosci. 2014 May 14;34(20):6985-92
pubmed: 24828651
Br J Clin Pharmacol. 2017 Mar;83(3):517-526
pubmed: 27650681
Am J Physiol Regul Integr Comp Physiol. 2011 Oct;301(4):R1011-24
pubmed: 21775649
Biochim Biophys Acta. 2001 Mar 9;1546(1):79-86
pubmed: 11257510
Diabetes Obes Metab. 2011 May;13(5):426-33
pubmed: 21251178
Lancet. 1987 Dec 5;2(8571):1300-4
pubmed: 2890903
Pharmacol Ther. 2019 Apr;196:1-14
pubmed: 30439457
J Med Chem. 2000 May 4;43(9):1664-9
pubmed: 10794683
Addict Biol. 2021 May;26(3):e12953
pubmed: 32770792
Psychoneuroendocrinology. 2013 Aug;38(8):1259-70
pubmed: 23219472
Psychoneuroendocrinology. 2016 Mar;65:54-66
pubmed: 26724568
Br J Pharmacol. 2014 Aug;171(15):3651-65
pubmed: 24712679
Diabetes. 2015 Jan;64(1):79-89
pubmed: 25114295
Science. 1999 Nov 26;286(5445):1745-9
pubmed: 10576743
J Neurosci Methods. 1991 Feb;36(2-3):219-28
pubmed: 2062117
Psychoneuroendocrinology. 2019 May;103:284-295
pubmed: 30771711
Toxicol Pathol. 2015 Dec;43(8):1093-102
pubmed: 26269615
Behav Brain Res. 2006 Jan 30;166(2):189-96
pubmed: 16153716
Cogent Biol. 2016 Dec 31;2(1):1229086
pubmed: 27722184
Endocrinology. 1988 Oct;123(4):2009-13
pubmed: 2901341
Nat Med. 2003 Sep;9(9):1173-9
pubmed: 12925848
Neuropharmacology. 1998 Apr-May;37(4-5):407-19
pubmed: 9704982
Diabetes Obes Metab. 2010 Oct;12(10):891-9
pubmed: 20920042
Diabetologia. 2002 Feb;45(2):195-202
pubmed: 11935150
J Neurosci. 2012 Apr 4;32(14):4812-20
pubmed: 22492036
Pharmacol Biochem Behav. 2016 Mar;142:48-55
pubmed: 26701752
PLoS One. 2013 Apr 16;8(4):e61965
pubmed: 23613987
Nature. 2005 Oct 20;437(7062):1158-61
pubmed: 16237445
Lancet. 2009 Jul 4;374(9683):39-47
pubmed: 19515413
Addict Biol. 2020 May;25(3):e12757
pubmed: 30969011
Int J Obes Relat Metab Disord. 2003 Mar;27(3):313-8
pubmed: 12629557
Endocrinology. 2012 Feb;153(2):647-58
pubmed: 22128031
Addict Biol. 2019 Mar;24(2):170-181
pubmed: 29226617
Peptides. 2012 May;35(1):1-8
pubmed: 22465882
Eur J Pharmacol. 2011 Jan 10;650(1):249-55
pubmed: 20951130
Addict Biol. 2016 Mar;21(2):422-37
pubmed: 26303264
BMC Pharmacol Toxicol. 2017 Dec 16;18(1):83
pubmed: 29246184
Addict Biol. 2012 Jan;17(1):86-94
pubmed: 21309944
BMC Neurosci. 2012 Mar 23;13:33
pubmed: 22443187
Psychoneuroendocrinology. 2015 Dec;62:392-402
pubmed: 26398679
Brain Res Brain Res Rev. 1993 Sep-Dec;18(3):247-91
pubmed: 8401595
Ann Pharmacother. 2012 Dec;46(12):1700-6
pubmed: 23191935
Am J Physiol Regul Integr Comp Physiol. 2016 May 15;310(10):R885-95
pubmed: 27030669